Chronic Experimental Diabetes Accelerates Urinary Elimination of Deprenyl and its Metabolites



Ernest Adeghate*, 1, Péter Sótonyi, Jr2, Huba Kalász3, §
1 Department of Anatomy, Faculty of Medicine & Health Sciences, United Arab Emirates University, Al Ain, P.O. Box 17666, United Arab Emirates
2 Department of Cardiovascular Surgery, Semmelwies University, Budapest, Hungary
3 Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, P.O. Box 370, Hungary 1445


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 718
Abstract HTML Views: 401
PDF Downloads: 162
Total Views/Downloads: 1281
Unique Statistics:

Full-Text HTML Views: 364
Abstract HTML Views: 214
PDF Downloads: 91
Total Views/Downloads: 669



2008 Bentham Science Publishers Ltd.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the Department of Anatomy, Faculty of Medicine & Health Sciences, United Arab Emirates University, Al Ain, P.O. Box 17666, United Arab Emirates Tel: +971-3-7672033 Fax: +971-3-7137496 E-mail: eadeghate@uaeu.ac.ae
§ Present Address: Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, United Arab Emirates University, Al Ain, P. O. Box 17666, United Arab Emirates


Abstract

Many diabetic patients take several medications to treat diabetes-associated complications and other ailments. The mode of elimination of these drugs and their metabolites are poorly understood. The elimination of deprenyl, a MAO-B inhibitor, used for the treatment of the early stage of Parkinson’s disease and senile dementia was investigated using thin layer chromatography.

Male Wistar rats (180-200 g) were rendered diabetic by streptozotocin (STZ) treatment (60 mg/kg, i.v.). Rats having at least three times higher plasma glucose level than the normal were considered diabetic. Rats were treated with a single oral dose of 5 mg/kg 14C-(methyl)-labeled (-)-deprenyl, 98 (Ci/mg. Diabetic rats excreted the majority of urinary radioactivity in 8 hours, while control rats did it in 16 hours. The approximate ratio of major metabolites as determined using thin-layer chromatography did not change. In conclusion, diabetic rats excreted radiolabelled-deprenyl more rapidly compared to control animals. Increased elimination of deprenyl should be taken into account in the management of patients suffering from diabetes.

Keywords: Deprenyl, diabetes, pharmacokinetics, urinary elimination.